ABOUT R&D PIPELINE INVESTORS & MEDIA CAREERS Powerful Biology. Novel Medicines. Transformative Impact. LATEST NEWS We presented preliminary findings from our ongoing Phase 1a/1b dose escalation study of NGM120 in patients with advanced solid tumors at the ESMO Virtual Congress 2021. LEARN MORE 1 2 3 4 5 6 7 OUR PIPELINE We aspire to operate one of the most productive R&D engines in the biopharma industry. Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients. EXPLORE OUR PIPELINE We have built our company around core scientific values that frame our approach to drug discovery and development. Our Core Values Latest News NOV 09 NGM Bio to Participate in Upcoming Investor Conferences NOV 04 NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results SEP 16 NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021 VIEW ALL PRESS RELEASES NGM621 for Geographic Atrophy (GA) NGM621, our anti-complement C3 antibody, is currently in Phase 2 study (CATALINA) as a treatment to potentially reduce disease progression in patients with GA and with the potential for every eight week dosing. LEARN MORE Working Here Our People Are Our Platform. What makes NGM tick? Really smart team members who love working together to pursue great science and share a common drive to deliver a huge impact for patients. We have no hierarchies. We collaborate intensively, embrace risk freely and always swing for the fence. JOIN US © 2021 NGM Biopharmaceuticals. All Rights Reserved. Contact. Privacy Policy. Terms of Use.